Pharmaceutical

ND-10 ER by Theialife Sciences for Myopia: Likelihood of Approval

ND-10 ER is under clinical development by Theialife Sciences and currently in Phase II for Myopia.

Dec 20, 2023 - 18:00
ND-10 ER is under clinical development by Theialife Sciences and currently in Phase II for Myopia.
Read the original article

Tags:

Previous Article

FLU-SV-mRNA by Curevac for Influenza A Virus, H1N1 Subtype Infections: Likelihoo...

Next Article

MABS-139 by Manhattan Biosolutions for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: After Sarepta trial failure, families and doctors brace for another debate on Duchenne therapy

STAT+: After Sarepta trial failure, families and doctor...

Nov 1, 2023

Bicycle Therapeutics gets grant for high affinity binde...

Apr 25, 2024

Risk adjusted net present value: What is the current va...

Mar 13, 2024